Patent intelligence · US
US 9260726
Targeted integration and expression on exogenous nucleic acid sequences
Targeted integration and expression on exogenous nucleic acid sequences
Patent details — US 9260726
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 16, 2016
- Expiration
- Feb 11, 2036
- Applicant
- Sangamo Biosciences, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K48/0008, A61K48/005, A61K48/0058
Quick answer
US 9260726 (Targeted integration and expression on exogenous nucleic acid sequences) is held by Sangamo Biosciences, Inc.. Status: granted. Granted Feb 16, 2016. Expires Feb 11, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sangamo Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K48/0008, A61K48/005, A61K48/0058
More from Sangamo Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12318427
Methods and compositions for modulation of tau proteins
granted -
US 12139517
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
granted -
US 12043650
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
granted -
US 11981967
Engineering AAV
granted -
US 11981739
Chimeric antigen receptor specific for interleukin-23 receptor
granted -
US 11920169
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 11898158
Methods and compositions for the treatment of lysosomal storage diseases
granted -
US 11884930
Method of inactivating a glucocorticoid receptor gene in an isolated cell
granted
Frequently asked questions
What is US patent 9260726?
US 9260726 (Targeted integration and expression on exogenous nucleic acid sequences) is held by Sangamo Biosciences, Inc.. Status: granted. Granted Feb 16, 2016. Expires Feb 11, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9260726?
Sangamo Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 192 pharmaceutical patents for this assignee.
When does US 9260726 expire?
Our index shows an expiration date of Feb 11, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.